Oncogenic signaling mutations in JAK2^V617F and NRAS both result in granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity, a finding in >90% of CMML cases [16]. The gene discussed is JAK2; the disease is chronic myelomonocytic leukemia.